

## **PV and Thrombosis**

<b>Time</b>	<b>Question</b>
<b>00:30</b>	<b>Discussion of thrombosis risk assessment in polycythemia vera patients.</b>
<b>02:32</b>	<b>Does baby aspirin provide a protective effect?</b>
<b>03:55</b>	<b>What is aspirin's role in this disease? Should we then think about alternative, different kind of antiplatelet or anticoagulation factor for all the PV patients?</b>
<b>09:18</b>	<b>What are the challenges of a patient with a vascular event?</b>
<b>12:27</b>	<b>Should testing for JAK2 mutation be standard practice?</b>
<b>16:18</b>	<b>Is Coumadin or warfarin still the gold standard anticoagulation therapy, or should we be thinking about alternatives?</b>
<b>17:27</b>	<b>Is there a need to bring a cardiologist in as a consult in management of polycythemia vera patients?</b>